Related Experiment Videos
[Clinical experience with sustained release cefalexin (S-6437) for pediatric use in pediatrics (author's transl)]
Insights
S-6437, a sustained-release cefalexin formulation, demonstrated high effectiveness in treating pediatric infections with a twice-daily regimen. This convenient dosing improves upon standard cefalexin administration.
Area of Science:
- Pharmacology
- Pediatric Infectious Diseases
- Drug Delivery Systems
Context:
- Cephalexin is a widely used antibiotic, but its standard formulation requires frequent dosing.
- Pediatric infections necessitate effective and convenient treatment options.
- Sustained-release drug formulations aim to improve patient compliance and therapeutic outcomes.
Purpose:
- To evaluate the efficacy and safety of S-6437, a novel sustained-release cefalexin preparation, in pediatric patients.
- To assess the effectiveness of a twice-daily (b.i.d.) regimen of S-6437 for various infections.
- To compare the administration convenience of S-6437 with standard cefalexin.
Summary:
- S-6437, a combination of non-enteric and enteric-coated granules, was administered at 40-100 mg/kg/day in two divided doses.
- Overall effectiveness was 82.1% (23/28 cases), with 87.0% response in respiratory tract infections and 60.0% in other infections.
- Mild diarrhea was the most common side effect (17.2%), with no severe adverse events reported.
Impact:
- S-6437 offers a more convenient dosing schedule compared to standard cefalexin, potentially improving adherence.
- The study supports the use of S-6437 as an effective treatment option for pediatric infections.
- This sustained-release formulation addresses a key limitation of conventional cefalexin therapy.
Abstract:
S-6437 is a preparation of sustained release cefalexin consisting of non-enteric coated granules and enteric coates ones and it is reported that the drug shows good effectiveness with b.i.d. regimen. Various infections in pediatrics were treated with S-6437 and the following results were obtained. Dose used was 40 approximately 100 mg/kg/day at 2 divided doses after breakfast and dinner. 1) Twenty patients (87.0%) of the 23 with respiratory tract infections and 3 (60.0%) of the 5 with the other infections responded to the drug. Overall effectiveness was 82.1% (23/28 cases). 2) As for side effects, tentative diarrhea was observed in 5 patients (17.2%) of the 29 but no other severe side effects were found. 3) S-6437 is considered to be a drug which overcomes inconvenience of giving regular cefalexin four times a day.